Antibody-drug conjugates are rapidly reshaping precision oncology. With 15 FDA-approved therapies and hundreds more in development, ADCs combine targeted antibodies with potent payloads to improve efficacy and reduce toxicity. Click the button below to read how advances in linker chemistry, dual payloads, and AI-driven trial design are driving innovation and positioning ADCs to account for a significant share of oncology spending by 2029.

Featured Contributors:

Amanda L. Potocky, Director, Clinical Project Management, Immuno-Oncology and Cell and Gene Therapy Oncology, IQVIA Biotech

Scott Bazemore, Senior Director, Oncology Therapeutic Strategy Lead, Therapeutic Science and Strategy, IQVIA

Jaba Kokhreidze, Senior Medical Director, Oncology Center of Excellence, IQVIA